BioSpace News Archive

- RGX-121, a one-time gene therapy for MPS II, continues to be well-tolerated with no drug-related serious adverse events - Biomarkers and measures of neurodevelopmental function from patients in Cohort 1 and 2 indicate CNS activity following RGX-121 administration -- Consistent reductions in CSF levels of biomarkers up to 2 years after RGX-121 administration

- IND-Enabling Studies Demonstrated Potential of a Single I.V. Administration of HMI-203 to Address Peripheral and CNS Components of Disease - - Data at WORLD Symposium ™ Support Plans to Initiate a HMI-203 Phase 1/2 Clinical Trial This Year

Metazoa, developers of the Salesforce ecosystem’s top software toolset for org management, today announced that Metazoa Snapshot has been optimized to support Salesforce Vaccine Cloud.

As consumer awareness for vitamins and supplements continue to proliferate, vitamin K market size is expected to grow considerably.

The ADNAB™ platform was developed and exclusively licensed to Sorrento by the Mayo Clinic Clinical studies utilizing the ADNAB™ platform are ongoing at the Mayo Clinic; and are evaluating multiple platform-generated products in advanced-stage: endometrial cancer, ovarian cancer, angiosarcoma, and B-Cell lymphomas Study LS1681 is a Mayo Investigator-Initiated-Trial (IIT) for relapsed or refractory B-cell lymphomas; and is evaluating rituximab-ADNAB™

InspireMD, Inc. (“InspireMD”) (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the closing of an upsized underwritten public offering of units for gross proceeds of approximately $20.7 million,

Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the closing of an underwritten public offering of 6,666,666 shares of common stock at a public offering price of $45.00 per share, before underwriting discounts and commissions.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA / TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that, it has closed its previously announced public offering (the “Offering”) of 1,616,293 common shares of the Company (the “Common Shares”),

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Dong Yu, Ph.D., has joined the Company as Senior Vice President of Vaccine Research and a member of the Executive Team.